Elsevier

Journal of Hepatology

Volume 47, Issue 4, October 2007, Pages 455-459
Journal of Hepatology

Forum on Liver Transplantation
Special Section Editor and Associate Editor: Pierre-Alain Clavien
Cholangiocarcinoma: Is transplantation an option? For whom?

https://doi.org/10.1016/j.jhep.2007.07.003Get rights and content

Introduction

Ductular cholangiocarcinoma is a cancer with features of bile duct epithelial cell differentiation. Given this phenotype it is presumed to originate from bile epithelial cells, although it may also originate from periductular glands. It has a unique propensity to arise within the perihilar region of the liver affecting the right and/or left hepatic bile ducts and their union to form the common hepatic duct. Why this cancer affects these bile ducts and this region of the liver remains biologically enigmatic, but is important clinically. It is a desmoplastic cancer which results in bile duct stricturing and obstruction, a cardinal feature of its clinical presentation. Although bile is generally regarded as a noxious substance, this cancer has a tropism for bile and often extends along the bile ducts and resists growing tangentially or radially away from the bile ducts. This tropism likely results from the ability of bile acids to transactivate the epidermal growth factor receptor in this cell type [1]. Once a mass lesion is apparent, the cancer is quite advanced as it has developed self-sustaining growth characteristics and no longer requires the nutrient biliary stream for survival. An understanding of the composite biological features described above is critical and fundamental to its diagnosis and management. First, because of its perihilar location, this cancer encases (but infrequently invades) the portal vein and hepatic artery. Its extension directly into the liver or into the right and left secondary biliary branches with or without vascular encasement frequently precludes hepatic resection [2]. Second, its growth along rather than radially from the bile ducts due to its tropism for bile often fails to produce a mass lesion on cross-sectional imaging studies despite biliary obstruction. Third, the desmoplastic features of this cancer make it difficult to obtain a diagnosis. Endoscopic obtained brushings are often negative and only have a diagnostic sensitivity of 20–40%. Finally, this cancer predominantly recurs regionally which implies persistent micrometastatic nodal disease or disease at the margins of resection despite extended surgical resection. This regional recurrence is frequent and devastating and survival after apparent curative resection is only 20–40% at 5 years [3]. Adjuvant approaches to better control regional disease combined with operation should result in enhanced clinical outcomes.

The majority of cholangiocarcinomas arise in the absence of risk factors [4]. However, chronic bile duct inflammation is a well-recognized risk factor for this neoplasm. In particular, primary sclerosing cholangitis (PSC), an inflammatory disease of large bile ducts, clearly and unquestionably predisposes to the development of this cancer. Up to 10% of patients with cholangiocarcinoma in the United States have PSC [5], [6]. The presence of underlying PSC confounds the diagnosis and management of superimposed cholangiocarcinoma. The differentiation between a benign and malignant stricture in patients with PSC is problematic. Moreover, cholangiocarcinoma with PSC is frequently multicentric. Finally, like hepatocellular carcinoma occurring in cirrhosis, the presence of cholangiocarcinoma in PSC is frequently complicated by chronic parenchymal liver disease, cirrhosis and portal hypertension. It is not surprising therefore, that resection of cholangiocarcinoma in PSC can be considered futile [7].

These observations raise several key questions: (i) how can cholangiocarcinoma be best diagnosed definitively? (ii) If surgical resection is neither technically feasible nor rationale in patients with PSC, what is the role of liver transplantation in this setting? Our goal is to address these two issues in this mini-review.

Section snippets

Diagnosis of limited stage cholangiocarcinoma

If survival following liver transplantation is expected as a viable therapeutic modality, an early diagnosis of cholangiocarcinoma is not only desirable, but is essential for cure. Therefore, early diagnostic criteria for cholangiocarcinoma need to be established and validated. In the absence of PSC, a de novo bile duct stricture involving the main right and left hepatic ducts and/or common hepatic duct is highly suspicious for cholangiocarcinoma. However, in all surgical series, 10–15% of such

Liver transplantation alone for limited stage cholangiocarcinoma

Liver transplantation for hepatocellular carcinoma has evolved over the last several decades. Patients undergoing liver transplantation for multicentric cancer, tumors >5 cm and those cancers manifesting vascular invasion frequently develop rapidly progressive, lethal, recurrent disease. In contrast, patients with unicentric cancers <5 cm or three lesions all less than <3 cm, without vascular invasion, are frequently cured by liver transplantation [14]. Although the role of neoadjuvant therapy for

When should liver transplantation be performed for cholangiocarcinoma?

First and foremost, the authors want to affirm an exceedingly conservative approach to an aggressive protocol. Like a legal document, text and phraseology is often open to interpretation. We emphasize that in all instances we have taken a conservative interpretation to our protocol declining participation for patients with criteria in the ‘gray area’. Consequently, it may be difficult to generalize this protocol to all transplant centers. Considerable resources, experience and effort have been

Acknowledgement

The authors thank Erin Bungum for the excellent secretarial assistance.

First page preview

First page preview
Click to open first page preview

References (24)

  • D.J. Rea et al.

    Major hepatic resection for hilar cholangiocarcinoma

    Arch Surg

    (2004)
  • H. Malhi et al.

    Review article: the modern diagnosis and therapy of cholangiocarcinoma

    Aliment Pharmacol Ther

    (2006)
  • Cited by (59)

    • Tumours and Tumour-Like Lesions

      2023, MacSween's Pathology of the Liver, Eighth Edition
    • Evaluation and Staging of Pancreaticobiliary Malignancy

      2019, Clinical Gastrointestinal Endoscopy
    • Tumours and Tumour-like Lesions of the Liver

      2018, MacSween's Pathology of the Liver
    • Cancer Risk and Surveillance in Primary Sclerosing Cholangitis

      2016, Clinics in Liver Disease
      Citation Excerpt :

      Following neoadjuvant therapy, liver transplantation can be considered in highly selected cases of limited-stage, unresectable, perihilar CCA with a 5-year survival rate of 65%.48 Liver transplantation following neoadjuvant therapy has been advocated in patients of limited-stage CCA, including patients with unicentric mass lesion less than or equal to 3 cm in radial diameter and no intrahepatic or extrahepatic metastases or TNM stage less than or equal to 2, and CA19-9 less than or equal to 100 IU/mL.49,50 Palliative treatment of patients not eligible for surgery includes endoscopic stenting, photodynamic therapy, and chemotherapy.51

    • Role of surgery in cholangiocarcinoma: From resection to transplantation

      2015, Best Practice and Research: Clinical Gastroenterology
    View all citing articles on Scopus

    The authors declare that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

    View full text